INNO-LIA® ANA Update

One run to identify 13 autoantigens

INNO-LIA ANA Update is a line immunoassay for the detection and identification of autoantibodies against nuclear and cytoplasmic antigens in human serum.

      CE marked
      INNO-LIA® ANA Update

      Product number 80047

      20 Tests
      Please contact your local Fujirebio representative for the availability of this product in your country.

      Click here to navigate

      • Details
      • Conditions of sale
      • Documentation
      • FAQ
      • Related products
      • Details

        Features & Benefits

        • Results for 13 antigens in one test run
        • Target specificity is 98% or more for all markers, combined with a high sensitivity
        • Visual interpretation or with scan software LiRAS® for LIA® ANA
        • Results within 3 hours
        • Fully automated processing of the strips possible using Auto-LIA™ 48

         
        Background

        Autoantibodies directed against distinct intracellular antigens can be detected in most of the systemic connective tissue diseases.

        Because characteristic profiles of autoantibodies are found in different diseases, determination of the specificity helps in establishing the correct diagnosis and facilitates the treatment and follow-up of the patient.

        Antibodies directed against antinuclear antibodies (ANA) are found in systemic connective tissue diseases.

        Some of these antibodies are very sensitive indicators of a certain disease, such as anti-RNP for mixed connective tissue disease (MCTD), but not specific.

        By contrast, other antibodies are more specific, such as anti-Sm in systemic lupus erythematosus (SLE), anti-Scl-70 in diffuse scleroderma, and anti-Jo-1 in polymyositis or dermatomyositis (PM/DM).

        In Sjögren's syndrome (SjS), no autoantibody is specific for the disease, but anti-SSA and anti-SSB show the best correlation.

        Also patients with SjS, secondary to SLE and rheumatoid arthritis (RA), show autoantibodies to SSA and SSB.

        The presence of mainly SSA antibodies during pregnancy has been associated with the development of congenital heart block in neonates.

        Patients with neurological complications to SLE may show ribosomal antibodies.

      • Conditions of sale

        To read the end user conditions of sale for this product please visit our Resource center.

      • FAQ